Malfunctioning enzyme may pave way for new MDS treatments

07/10/2013 | Drug Store News

Researchers have discovered a malfunctioning immune system enzyme that can be targeted to eliminate myelodysplastic syndrome-initiating clone cells. "Not only does our research implicate errant immune system signaling in MDS cells, it strongly indicates that inhibiting the function of this hijacked immune pathway may become an effective treatment option for MDS," said lead researcher Daniel Starczynowski. MDS, a blood disorder that precedes leukemia, has few effective therapies and can be cured only through a bone marrow transplant.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN